ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Veradigm Presentations at ISPOR 2022 Highlight Broader Access to and Integration of Real-world Data Sources

Covid-19 Dashboard highlights risk factors for unvaccinated, vaccination gaps, and social disparities

Researchers from Veradigm®, a leading provider of healthcare data and technology solutions, will present health economics and outcomes research (HEOR) data on Covid-19, diabetes, NASH (Non-Alcoholic Steatohepatitis), and cardiovascular disease at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Washington, D.C. from May 15-18, 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511005419/en/

“Accessing real-world data from across a variety of sources provides rich evidence for better decision-making and improved clinical outcomes for patients,” said Tom Langan, Allscripts President and Chief Commercial Officer. “We’re pleased to demonstrate how Veradigm provides tools that contribute to public health initiatives, like the Covid-19 Dashboard guiding outreach to underserved communities, or identifying risk factors with research that supports patients diagnosed with NASH earlier in their diagnosis or treatment.”

Key data presentations at ISPOR 2022 include:

Covid-19

Real-World Data Dashboard Integrating Public Health & EHR Data for Identifying COVID-19 Vaccination Gaps in the US. L. Kallenbach. CODE: EPH60. May 17th 9:45 AM – 1:15 PM EDT.

SARS-COV-2 Vaccine Breakthrough Infection Rates Based Data from 3 EHRS. J. Overcash. CODE: RWD72. May 17th 9:45 AM – 1:15 PM EDT.

NASH

Assessing Cardiovascular Disease (CVD) Risk By Fibrosis Stage Defined By Fibrosis-4 (FIB-4) Among Patients with Non-Alcoholic Steatohepatitis (NASH) Using Real World Data (RWD). A. Bogdanov. CODE: EPH141. May 18th 9:00 AM – 12:45 PM EDT.

Comparing Fibrosis Staging Approaches Among Patients with Non-Alcoholic Steatohepatitis (NASH) Using Real World Data (RWD). A. Bogdanov. CODE: EPH161. May 16th 3:00 – 6:30 PM EDT.

Diabetes

Comparing Techniques for Mining HBA1C Data in Ambulatory EHRS for Use in RWE Research. N. Nguyen. CODE: RWD52. May 16th 3:00 - 6:30 PM EDT.

Artificial Intelligence (AI)

Categorizing Telemedicine Visits Using Natural Language Processing and Machine Learning. T. Sudaria. CODE: RWD112. May 17th 3:00 - 6:30 PM EDT.

Evaluating a Privacy Preserving Record Linkage (PPRL) Solution to Link De-identified Patient Records in RWD Using Default Matching Methods and Machine Learning Methods. N. Nguyen. CODE: RWD103. May 17th 3:00 - 6:30 PM EDT.

Additional presentations at ISPOR include Veradigm’s Comparing Registry and Electronic Health Record (EHR) Data for Real-World Evidence Generation: Heart Failure as a Case Study on Tuesday, May 17 at 12:45 p.m. EDT. This presentation examines how generating real-world evidence (RWE) from heart failure patients requires clinical data elements not commonly found in administrative databases and has the potential to further understanding in heart failure management. Data were compared and contrasted from two different data sources, Veradigm’s PINNACLE® Registry, a large cardiovascular disease registry developed by the American College of Cardiology, with those identified in the Practice Fusion ambulatory electronic health record (EHR) database.

For more presentation information titles, please visit ISPOR 2022.

About Veradigm®

Veradigm® is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. Some healthcare technology companies deliver clinical data for biopharma and health plans, some help turn that data into insights, others serve healthcare providers directly by providing point-of-care clinical software and patient outreach platforms. Only Veradigm does it all. In combination with Veradigm’s companies and solutions, the Veradigm Network features a dynamic community of companies providing advanced insights, technology, and data-driven solutions, all working together to transform healthcare insightfully.

For more information on Veradigm, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2022 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  235.15
+1.27 (0.54%)
AAPL  285.55
+2.45 (0.87%)
AMD  217.31
-2.45 (-1.12%)
BAC  53.17
-0.07 (-0.13%)
GOOG  314.96
-0.16 (-0.05%)
META  643.65
+2.78 (0.43%)
MSFT  491.23
+4.49 (0.92%)
NVDA  181.49
+1.57 (0.87%)
ORCL  203.11
+2.17 (1.08%)
TSLA  423.97
-6.17 (-1.43%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.